Literature DB >> 21518328

Primitive erythropoiesis in infantile haemangioma.

T Itinteang1, S T Tan, H D Brasch, A Vishvanath, D J Day.   

Abstract

UNLABELLED: BACKGROUND; Infantile haemangioma (IH) is a tumour of the microvasculature composed predominantly of proliferating endothelial cells. It expresses markers associated with endothelial, haematopoietic and mesenchymal lineages. We have previously shown that the cells forming the capillary endothelium of proliferating IH express cell surface markers and transcriptions factors consistent with it being a haemogenic endothelium.
OBJECTIVES: We wished to determine whether the expression of transcription factors associated with the erythroid lineage was of physiological relevance and sufficient for IH tissue cultured in vitro to undergo erythropoiesis.
METHODS: Immunohistochemical staining of paraffin-embedded sections of proliferating IHs was undertaken and expression of the embryonically associated haemoglobin ζ (HBZ) chain and the erythropoietin receptor (EPO-R) was determined. Relative expression of mRNA encoding these proteins was determined by quantitative reverse transcription-polymerase chain reaction using snap-frozen biopsy samples. Differentiation towards erythrocytes was investigated using freshly resected tissue cultured as explants in Matrigel.
RESULTS: The endothelium of the microvessels, but not the pericyte layer, was strongly immunoreactive for the EPO-R and the embryonically associated HBZ chain. Abundant expression of transcripts encoding these proteins was also detected, corroborating the immunohistochemical staining. When tissue was grown in culture the cells emanating from IH explants were able to generate enucleated erythrocytes in vitro. The erythrocytes were immunoreactive for the erythrocyte-specific marker glycophorin A.
CONCLUSIONS: The microvessels in IH are a functional haemogenic endothelium that expresses the embryonically associated HBZ chain and is able to form erythrocytes in vitro. IH thus represents a possible extramedullary site for tumour-associated primitive erythropoiesis.
© 2011 The Authors. BJD © 2011 British Association of Dermatologists.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21518328     DOI: 10.1111/j.1365-2133.2010.10187.x

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN: 0007-0963            Impact factor:   9.302


  7 in total

Review 1.  Insights Into Vascular Anomalies, Cancer, and Fibroproliferative Conditions: The Role of Stem Cells and the Renin-Angiotensin System.

Authors:  Ethan J Kilmister; Swee T Tan
Journal:  Front Surg       Date:  2022-04-27

Review 2.  Biology of infantile hemangioma.

Authors:  Tinte Itinteang; Aaron H J Withers; Paul F Davis; Swee T Tan
Journal:  Front Surg       Date:  2014-09-25

3.  Elevated Serum Levels of Alpha-Fetoprotein in Patients with Infantile Hemangioma Are Not Derived from within the Tumor.

Authors:  Tinte Itinteang; Alice M Chibnall; Reginald Marsh; Jonathan C Dunne; Sophie de Jong; Paul F Davis; Philip Leadbitter; Swee T Tan
Journal:  Front Surg       Date:  2016-02-09

4.  Proliferating Infantile Hemangioma Tissues and Primary Cell Lines Express Markers Associated with Endothelial-to-Mesenchymal Transition.

Authors:  Tinte Itinteang; Cherise E S Tan; Bede van Schaijik; Reginald W Marsh; Paul F Davis; Swee T Tan
Journal:  Plast Reconstr Surg Glob Open       Date:  2020-02-11

Review 5.  Cell Populations Expressing Stemness-Associated Markers in Vascular Anomalies.

Authors:  Ethan J Kilmister; Lauren Hansen; Paul F Davis; Sean R R Hall; Swee T Tan
Journal:  Front Surg       Date:  2021-02-09

Review 6.  The modern primitives: applying new technological approaches to explore the biology of the earliest red blood cells.

Authors:  Stuart T Fraser
Journal:  ISRN Hematol       Date:  2013-10-03

7.  Phosphorylated Forms of STAT1, STAT3 and STAT5 Are Expressed in Proliferating but Not Involuted Infantile Hemangioma.

Authors:  Lucy Sulzberger; Elysia M S Tan; Paul F Davis; Helen D Brasch; Swee T Tan; Tinte Itinteang
Journal:  Front Surg       Date:  2018-04-19
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.